NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
17
AGL Quote, Financials, Valuation and Earnings
Last price:
$1.84
Seasonality move
:
-1.01%
Day range:
$1.83 - $1.99
52-week range:
$1.50 - $13.28
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.14x
P/B ratio:
1.41x
Volume:
5.2M
Avg. volume:
4.6M
1-year change:
-84.02%
Market cap:
$811.7M
Revenue:
$4.3B
EPS (TTM):
-$0.93
Analysts' Opinion
-
Consensus RatingAgilon Health has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 16 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $2.86, Agilon Health has an estimated upside of 45.42% from its current price of $1.97.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.75 representing 11.17% downside risk from its current price of $1.97.
Fair Value
-
According to the consensus of 19 analysts, Agilon Health has 45.42% upside to fair value with a price target of $2.86 per share.
AGL vs. S&P 500
-
Over the past 5 trading days, Agilon Health has underperformed the S&P 500 by -10.27% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Agilon Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Agilon Health has grown year-over-year revenues for 11 quarters straight. In the most recent quarter Agilon Health reported revenues of $1.5B.
Earnings Growth
-
Agilon Health has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Agilon Health reported earnings per share of -$0.29.
Enterprise value:
453.6M
EV / Invested capital:
0.74x
Price / LTM sales:
0.14x
EV / EBIT:
--
EV / Revenue:
0.08x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-2.53x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$51.8M
Return On Assets:
-18.17%
Net Income Margin (TTM):
-6.88%
Return On Equity:
-55.42%
Return On Invested Capital:
-52.59%
Operating Margin:
-9.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $2.2B | $3.6B | $5.6B | $1.1B | $1.5B | |
| Gross Profit | $101.2M | $173.6M | -$51.8M | $36.8M | -$64.2M | |
| Operating Income | -$77.5M | -$121.9M | -$348.3M | -$39.3M | -$133.5M | |
| EBITDA | -$68.2M | -$43.3M | -$281.3M | -$13.9M | -$109.2M | |
| Diluted EPS | -$0.26 | -$0.22 | -$0.93 | -$0.08 | -$0.29 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $1.5B | $1.6B | $2B | $1.8B | |
| Total Assets | -- | $1.7B | $1.9B | $2.3B | $2.1B | |
| Current Liabilities | -- | $422.8M | $658.2M | $1.3B | $1.4B | |
| Total Liabilities | -- | $557.7M | $785.1M | $1.4B | $1.5B | |
| Total Equity | -- | $1.1B | $1.1B | $871.6M | $574.9M | |
| Total Debt | -- | $49.6M | $44.7M | $39.8M | $34.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$129.7M | -$145M | -$135.4M | -$13M | -$7.7M | |
| Cash From Investing | -$439M | -$49.8M | $114M | -$11M | $46.6M | |
| Cash From Financing | $37.3M | -$191.2M | -$3.4M | $1.4M | -$1.4M | |
| Free Cash Flow | -$157.6M | -$168.7M | -$179.6M | -$18.8M | -$12.2M | |
AGL
Sector
Market Cap
$811.7M
$43.9M
Price % of 52-Week High
14.83%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
-0.02%
-0.74%
1-Year Price Total Return
-84.02%
-29.11%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.06
200-day SMA
Sell
Level
$4.59
Bollinger Bands (100)
Sell
Level
2.07 - 4.59
Chaikin Money Flow
Sell
Level
-68.4M
20-day SMA
Sell
Level
$2.11
Relative Strength Index (RSI14)
Sell
Level
44.11
ADX Line
Sell
Level
11.17
Williams %R
Neutral
Level
-67.9245
50-day SMA
Sell
Level
$2.34
MACD (12, 26)
Sell
Level
-0.09
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Sell
Level
-280.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.2369)
Buy
CA Score
(Annual)
Level (0.0083)
Sell
Beneish M-Score
(Annual)
Level (-1.0699)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (1.1575)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
Stock Forecast FAQ
In the current month, AGL has received 2 Buy ratings 16 Hold ratings, and 1 Sell ratings. The AGL average analyst price target in the past 3 months is $2.86.
-
Where Will Agilon Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Agilon Health share price will rise to $2.86 per share over the next 12 months.
-
What Do Analysts Say About Agilon Health?
Analysts are divided on their view about Agilon Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Agilon Health is a Sell and believe this share price will drop from its current level to $1.75.
-
What Is Agilon Health's Price Target?
The price target for Agilon Health over the next 1-year time period is forecast to be $2.86 according to 19 Wall Street analysts, 2 of them rate the stock a Buy, 1 rates the stock a Sell, and 16 analysts rate the stock a Hold.
-
Is AGL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Agilon Health is a Hold. 16 of 19 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of AGL?
You can purchase shares of Agilon Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Agilon Health shares.
-
What Is The Agilon Health Share Price Today?
Agilon Health was last trading at $1.84 per share. This represents the most recent stock quote for Agilon Health. Yesterday, Agilon Health closed at $1.97 per share.
-
How To Buy Agilon Health Stock Online?
In order to purchase Agilon Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 4.46% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 12.53% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 5.24% over the past day.
